Cover Image

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease

Immune checkpoint inhibitors (ICI) have revolutionized the treatment of many malignancies in recent years. However, immune−related adverse events (irAE) are a frequent concern in clinical practice. The safety profile of ICI for the treatment of malignancies in patients diagnosed with autoimmune and...

Full description

Saved in:
Bibliographic Details
Main Authors: Kocheise, Lorenz (Author) , Piseddu, Ignazio (Author) , Vonderlin, Joscha (Author) , Tjwa, Eric T. (Author) , Buescher, Gustav (Author) , Meunier, Lucy (Author) , Goeggelmann, Pia (Author) , Fianchi, Francesca (Author) , Dumortier, Jérôme Roland Jean-Pierre Bernadin (Author) , Riveiro Barciela, Mar (Author) , Gevers, Tom J.G. (Author) , Terziroli Beretta-Piccoli, Benedetta (Author) , Londoño, Maria-Carlota (Author) , Frankova, Sona (Author) , Rösner, Thomas (Author) , Joerg, Vincent (Author) , Schmidt, Constantin (Author) , Glaser, Fabian (Author) , Sutter, Jan (Author) , Fründt, Thorben Wilhelm (Author) , Lohse, Ansgar W. (Author) , Huber, Samuel (Author) , Felden, Johann von (Author) , Sebode, Marcial (Author) , Schulze, Kornelius (Author)
Format: Article (Journal)
Language:English
Published: 10 January 2024
In: Frontiers in immunology
Year: 2024, Volume: 14, Pages: 1-9
ISSN:1664-3224
DOI:10.3389/fimmu.2023.1326078
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3389/fimmu.2023.1326078
Verlag, kostenfrei, Volltext: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1326078/full
Get full text
Author Notes:Lorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, Eric T. Tjwa, Gustav Buescher, Lucy Meunier, Pia Goeggelmann, Francesca Fianchi, Jérôme Dumortier, Mar Riveiro Barciela, Tom J. G. Gevers, Benedetta Terziroli Beretta-Piccoli, Maria-Carlota Londoño, Sona Frankova, Thomas Roesner, Vincent Joerg, Constantin Schmidt, Fabian Glaser, Jan P. Sutter, Thorben W. Fründt, Ansgar W. Lohse, Samuel Huber, Johann von Felden, Marcial Sebode and Kornelius Schulze
Description
Summary:Immune checkpoint inhibitors (ICI) have revolutionized the treatment of many malignancies in recent years. However, immune−related adverse events (irAE) are a frequent concern in clinical practice. The safety profile of ICI for the treatment of malignancies in patients diagnosed with autoimmune and cholestatic liver disease (AILD) remains unclear. Due to this uncertainty, these patients were excluded from ICI clinical trials and ICI are withheld from this patient group. In this retrospective multicenter study, we assessed the safety of ICI in patients with AILD.
Item Description:Gesehen am 26.03.2024
Physical Description:Online Resource
ISSN:1664-3224
DOI:10.3389/fimmu.2023.1326078

Similar Items